Navtemadlin

N/A

Report date: 2024/08/07 16:03:24
NME

Base Information

Drug NameNavtemadlin
Drug Alias NameAMG-232KRT-232KRT232
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisEndometrial Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteKartos Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisEndometrial NeoplasmsPolycythemia Vera +[7] 
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksN/A